 Sheryl Vondracek
Concepts (122)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Osteoporosis | 5 | 2009 | 231 | 1.180 |
Why?
| | Antihypertensive Agents | 2 | 2018 | 485 | 0.830 |
Why?
| | Vitamin D | 6 | 2012 | 380 | 0.810 |
Why?
| | Nephrologists | 1 | 2021 | 12 | 0.730 |
Why?
| | Bone Density Conservation Agents | 3 | 2010 | 70 | 0.650 |
Why?
| | Vitamin D Deficiency | 5 | 2012 | 177 | 0.580 |
Why?
| | Hypertension | 2 | 2018 | 1242 | 0.580 |
Why?
| | Adrenergic Antagonists | 1 | 2018 | 8 | 0.580 |
Why?
| | Hydralazine | 1 | 2018 | 4 | 0.580 |
Why?
| | Labetalol | 1 | 2018 | 7 | 0.580 |
Why?
| | Glomerular Filtration Rate | 1 | 2021 | 711 | 0.560 |
Why?
| | Kidney Diseases | 1 | 2021 | 382 | 0.560 |
Why?
| | Asymptomatic Diseases | 1 | 2016 | 84 | 0.510 |
Why?
| | Vasodilator Agents | 1 | 2018 | 326 | 0.500 |
Why?
| | Ergocalciferols | 2 | 2012 | 11 | 0.480 |
Why?
| | Pulmonary Disease, Chronic Obstructive | 3 | 2009 | 1000 | 0.470 |
Why?
| | Curriculum | 1 | 2021 | 925 | 0.460 |
Why?
| | Bone Density | 4 | 2015 | 463 | 0.450 |
Why?
| | Kidney | 1 | 2021 | 1383 | 0.430 |
Why?
| | Glucocorticoids | 2 | 2006 | 582 | 0.370 |
Why?
| | Receptors, Calcitriol | 1 | 2011 | 53 | 0.360 |
Why?
| | Hospitalization | 2 | 2018 | 2075 | 0.360 |
Why?
| | Blood Pressure | 1 | 2018 | 1736 | 0.350 |
Why?
| | Prescription Drugs | 1 | 2012 | 112 | 0.340 |
Why?
| | Body Composition | 2 | 2015 | 649 | 0.330 |
Why?
| | Osteoporosis, Postmenopausal | 1 | 2010 | 39 | 0.330 |
Why?
| | Adipokines | 1 | 2009 | 47 | 0.310 |
Why?
| | Geriatric Nursing | 1 | 2009 | 22 | 0.310 |
Why?
| | Premenopause | 1 | 2009 | 120 | 0.300 |
Why?
| | Risk Reduction Behavior | 1 | 2010 | 209 | 0.290 |
Why?
| | Administration, Intravenous | 2 | 2018 | 141 | 0.260 |
Why?
| | Kidney Failure, Chronic | 1 | 2011 | 546 | 0.240 |
Why?
| | Prednisone | 1 | 2006 | 234 | 0.240 |
Why?
| | Acute Disease | 3 | 2018 | 980 | 0.220 |
Why?
| | Hospitals, University | 2 | 2018 | 180 | 0.200 |
Why?
| | Severity of Illness Index | 3 | 2018 | 2739 | 0.180 |
Why?
| | Drug Therapy, Combination | 3 | 2015 | 1042 | 0.160 |
Why?
| | Aged | 8 | 2018 | 22101 | 0.150 |
Why?
| | Absorptiometry, Photon | 2 | 2009 | 247 | 0.150 |
Why?
| | Drug Utilization Review | 1 | 2018 | 57 | 0.140 |
Why?
| | Electronic Health Records | 2 | 2018 | 975 | 0.140 |
Why?
| | Humans | 18 | 2021 | 129687 | 0.140 |
Why?
| | Time Factors | 2 | 2018 | 6545 | 0.130 |
Why?
| | Pharmacists | 2 | 2010 | 247 | 0.130 |
Why?
| | Vitamins | 2 | 2008 | 173 | 0.130 |
Why?
| | Aged, 80 and over | 5 | 2012 | 7064 | 0.120 |
Why?
| | Blood Pressure Determination | 1 | 2016 | 148 | 0.120 |
Why?
| | Estrogens, Conjugated (USP) | 1 | 2015 | 46 | 0.120 |
Why?
| | Administration, Oral | 1 | 2018 | 787 | 0.120 |
Why?
| | Drug Administration Schedule | 2 | 2006 | 766 | 0.110 |
Why?
| | Gonadotropin-Releasing Hormone | 1 | 2015 | 204 | 0.110 |
Why?
| | Fractures, Bone | 2 | 2009 | 394 | 0.110 |
Why?
| | Female | 10 | 2018 | 68751 | 0.100 |
Why?
| | Drug Evaluation | 1 | 2012 | 82 | 0.100 |
Why?
| | Colorado | 4 | 2018 | 4405 | 0.100 |
Why?
| | Prevalence | 2 | 2016 | 2563 | 0.090 |
Why?
| | Professional Role | 2 | 2010 | 158 | 0.090 |
Why?
| | Dose-Response Relationship, Drug | 2 | 2015 | 2014 | 0.090 |
Why?
| | Exercise | 2 | 2015 | 1933 | 0.090 |
Why?
| | Retrospective Studies | 3 | 2018 | 14525 | 0.090 |
Why?
| | Cholecalciferol | 1 | 2011 | 56 | 0.090 |
Why?
| | Bone Resorption | 1 | 2011 | 80 | 0.090 |
Why?
| | Male | 8 | 2018 | 63691 | 0.090 |
Why?
| | Contraindications | 1 | 2010 | 90 | 0.080 |
Why?
| | Resistin | 1 | 2009 | 11 | 0.080 |
Why?
| | Bone Remodeling | 1 | 2010 | 71 | 0.080 |
Why?
| | Biological Factors | 1 | 2009 | 36 | 0.080 |
Why?
| | Practice Patterns, Physicians' | 1 | 2018 | 1271 | 0.080 |
Why?
| | Practice Guidelines as Topic | 1 | 2016 | 1506 | 0.080 |
Why?
| | Adult | 4 | 2018 | 35607 | 0.070 |
Why?
| | Middle Aged | 3 | 2018 | 31165 | 0.070 |
Why?
| | Leptin | 1 | 2009 | 222 | 0.070 |
Why?
| | Raloxifene Hydrochloride | 1 | 2008 | 16 | 0.070 |
Why?
| | Hip Joint | 1 | 2009 | 158 | 0.070 |
Why?
| | Diphosphonates | 1 | 2008 | 58 | 0.070 |
Why?
| | Adiponectin | 1 | 2009 | 236 | 0.070 |
Why?
| | Lumbar Vertebrae | 1 | 2009 | 234 | 0.070 |
Why?
| | Risk Assessment | 1 | 2016 | 3260 | 0.070 |
Why?
| | Accreditation | 1 | 2007 | 80 | 0.070 |
Why?
| | Community Pharmacy Services | 1 | 2007 | 43 | 0.070 |
Why?
| | Life Style | 1 | 2009 | 462 | 0.060 |
Why?
| | Hospital Bed Capacity, 300 to 499 | 1 | 2006 | 4 | 0.060 |
Why?
| | Calcium | 2 | 2010 | 1212 | 0.060 |
Why?
| | Drug Administration Routes | 1 | 2006 | 37 | 0.060 |
Why?
| | Pharmacy Service, Hospital | 1 | 2007 | 90 | 0.060 |
Why?
| | Treatment Outcome | 2 | 2018 | 10221 | 0.060 |
Why?
| | Women's Health | 1 | 2009 | 364 | 0.060 |
Why?
| | Preceptorship | 1 | 2006 | 63 | 0.060 |
Why?
| | Education, Pharmacy | 1 | 2007 | 119 | 0.060 |
Why?
| | Drug Utilization | 1 | 2006 | 171 | 0.060 |
Why?
| | Students, Pharmacy | 1 | 2006 | 96 | 0.060 |
Why?
| | Risk Factors | 3 | 2009 | 9787 | 0.060 |
Why?
| | Tumor Necrosis Factor-alpha | 1 | 2009 | 1204 | 0.060 |
Why?
| | Pilot Projects | 1 | 2009 | 1594 | 0.060 |
Why?
| | Educational Measurement | 1 | 2006 | 263 | 0.050 |
Why?
| | Patient Education as Topic | 1 | 2008 | 743 | 0.050 |
Why?
| | Recurrence | 1 | 2006 | 1012 | 0.050 |
Why?
| | Mass Screening | 1 | 2009 | 1192 | 0.050 |
Why?
| | Clinical Trials as Topic | 1 | 2006 | 1005 | 0.050 |
Why?
| | Cross-Sectional Studies | 2 | 2009 | 5083 | 0.040 |
Why?
| | Clinical Competence | 1 | 2007 | 1018 | 0.040 |
Why?
| | Diet | 1 | 2007 | 1212 | 0.040 |
Why?
| | Parathyroid Hormone | 2 | 2008 | 106 | 0.030 |
Why?
| | Lung | 1 | 2009 | 3937 | 0.030 |
Why?
| | Prognosis | 1 | 2004 | 3772 | 0.030 |
Why?
| | Young Adult | 1 | 2012 | 12457 | 0.030 |
Why?
| | Ovary | 1 | 2015 | 209 | 0.030 |
Why?
| | Ambulatory Care | 2 | 2008 | 506 | 0.030 |
Why?
| | Adolescent | 1 | 2012 | 20415 | 0.030 |
Why?
| | Self Administration | 1 | 2008 | 122 | 0.020 |
Why?
| | Pharmaceutical Services | 1 | 2008 | 81 | 0.020 |
Why?
| | Nutrition Policy | 1 | 2007 | 57 | 0.020 |
Why?
| | Phosphorus | 1 | 2007 | 92 | 0.020 |
Why?
| | Nonprescription Drugs | 1 | 2007 | 66 | 0.020 |
Why?
| | Serum Albumin | 1 | 2007 | 149 | 0.020 |
Why?
| | Schools, Pharmacy | 1 | 2006 | 46 | 0.020 |
Why?
| | Creatinine | 1 | 2007 | 490 | 0.010 |
Why?
| | Outpatients | 1 | 2007 | 374 | 0.010 |
Why?
| | Age Factors | 1 | 2007 | 3153 | 0.010 |
Why?
| | Follow-Up Studies | 1 | 2008 | 4892 | 0.010 |
Why?
| | Prospective Studies | 1 | 2007 | 7145 | 0.010 |
Why?
| | Obesity | 1 | 2007 | 2885 | 0.010 |
Why?
|
|
Vondracek's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|